Webinar: Evaluate alternative revolutionary reimbursement models to craft a sustainable business model for cell and gene therapies
During Reuter’s Cell and Gene Therapy USA 2022 conference, Senior Vice President, Market Economics, David Senior, was joined by fellow industry experts, Heather McDonald, Vice President, Market Access for CGT + Digital at Bayer, Burcu Kazazoglu Taylor, Senior Director, Global Value and Access, at Novartis Gene Therapies, and Michael Sherman, Executive Vice President and Chief Medical Officer at Point 32, to discuss new innovative payment strategies for cell and gene therapies.
Access the recording to learn more about the key features of successful innovative pricing and reimbursement models, and outcomes-based agreements in particular, and about the ways to advance those strategies for cell and gene therapies.

Related resources
[EXAMPLE SPOTLIGHT - PLEASE READ]
PLEASE REPLACE THIS SPOTLIGHT WITH AN APPROPRIATE CONTENT ITEM!
Change the associated content of this module by selecting one of the Full Image Spotlight content items in /Website Settings/Shared Content/Global Banners
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.